Product Description
Beijing Hope Pharmaceutical Co., Ltd. is a high-tech pharmaceutical company based in China and facing the world. The main business is R&D, production and sales of APIs and APIs, import and export trade, R&D of new pharmaceutical preparations and new drug registration. We have an R&D center in Beijing, a pharmaceutical intermediate production base in Hebei and Zhejiang, and a GMP-certified API production base in Shandong.
AI Product Description
*The following content is generated by AI and is for reference only.
Gliclazide is a second-generation sulfonylurea antidiabetic agent widely utilized in the management of type 2 diabetes mellitus. Chemically, its molecular formula is C15H21N3O3S, and it is identified by the CAS Registry Number 21829-25-4. This compound functions primarily by stimulating insulin secretion from pancreatic beta cells through the closure of ATP-sensitive potassium channels, thereby enhancing glucose-dependent insulin release. Unlike some first-generation agents, Gliclazide exhibits a more favorable pharmacokinetic profile with a shorter half-life, reducing the risk of prolonged hypoglycemia. It is available in various formulations, including immediate-release tablets for flexible dosing and modified-release (MR) capsules designed to provide sustained plasma concentrations over a 24-hour period, which improves patient compliance.
The primary clinical indication for Gliclazide is the control of hyperglycemia in adult patients with type 2 diabetes who have not achieved adequate glycemic control through diet, exercise, and weight loss alone. It is often prescribed as monotherapy or in combination with other oral antidiabetic drugs, such as metformin, or with insulin therapy when necessary. Beyond its glucose-lowering effects, emerging research suggests that Gliclazide may possess antioxidant properties, potentially offering vascular protective benefits against diabetic microvascular complications like retinopathy and nephropathy. Its mechanism involves not only increasing insulin sensitivity but also potentially improving endothelial function.
Common side effects include hypoglycemia, gastrointestinal disturbances, skin rashes, and weight gain. Patients must be monitored regularly for blood glucose levels, particularly during the initiation of therapy or dosage adjustments. Contraindications include type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and hypersensitivity to sulfonylureas. As a generic medication, Gliclazide is globally accessible and remains a cost-effective cornerstone in diabetes care protocols worldwide. Its efficacy, safety profile, and versatility make it a preferred choice for many clinicians managing chronic metabolic disorders. Proper patient education regarding dietary habits and symptom recognition of hypoglycemia is essential for optimal therapeutic outcomes.